JP7749169B2 - 中枢神経系障害を処置するための組成物および方法 - Google Patents
中枢神経系障害を処置するための組成物および方法Info
- Publication number
- JP7749169B2 JP7749169B2 JP2021572548A JP2021572548A JP7749169B2 JP 7749169 B2 JP7749169 B2 JP 7749169B2 JP 2021572548 A JP2021572548 A JP 2021572548A JP 2021572548 A JP2021572548 A JP 2021572548A JP 7749169 B2 JP7749169 B2 JP 7749169B2
- Authority
- JP
- Japan
- Prior art keywords
- suramin
- pharmaceutical composition
- composition
- less
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858621P | 2019-06-07 | 2019-06-07 | |
| US62/858,621 | 2019-06-07 | ||
| PCT/US2020/031217 WO2020247127A1 (en) | 2019-06-07 | 2020-05-02 | Compositions and methods for treating central nervous system disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535920A JP2022535920A (ja) | 2022-08-10 |
| JP2022535920A5 JP2022535920A5 (cg-RX-API-DMAC7.html) | 2023-05-23 |
| JP7749169B2 true JP7749169B2 (ja) | 2025-10-06 |
Family
ID=73652889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572548A Active JP7749169B2 (ja) | 2019-06-07 | 2020-05-02 | 中枢神経系障害を処置するための組成物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220226268A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3979985A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7749169B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114340597B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020288999A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3142842A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL288655A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020247127A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021319064A1 (en) * | 2020-07-29 | 2023-03-23 | Perfect Daylight Limited | Methods of manufacture of suramin |
| US20230390223A1 (en) * | 2020-10-22 | 2023-12-07 | Paxmedica, Inc. | Administration of antipurinergic compositions for treating nervous system disorders |
| EP4229035A4 (en) * | 2020-10-22 | 2024-07-31 | Paxmedica, Inc. | INTRANASALY ADMINISTRATION OF SURAMIN FOR THE TREATMENT OF NERVOUS SYSTEM DISEASES |
| JP2024532288A (ja) * | 2021-08-23 | 2024-09-05 | パックスメディカ, インコーポレイテッド | 抗プリン作動薬を用いて神経系障害を処置するための方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017529916A (ja) | 2014-09-02 | 2017-10-12 | トゥール・フランソワ=ラブレー大学 | 流体製品の鼻腔スプレー装置 |
| WO2018148262A1 (en) | 2017-02-08 | 2018-08-16 | Csp Pharma, Inc. | Antipurinergic compounds and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5012285A (en) * | 1984-10-12 | 1986-05-02 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav) |
| JP2003506458A (ja) * | 1999-08-11 | 2003-02-18 | ジョセフ ピサ, | シクロデキストリン誘導体の包接複合体形成の増強 |
| JP2005519075A (ja) * | 2002-02-25 | 2005-06-30 | リフジャスロウン エイチエフ | 吸収促進剤 |
| FR2867682B1 (fr) * | 2004-03-22 | 2009-06-05 | Galderma Res & Dev | Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise. |
| US20070292523A1 (en) * | 2004-09-27 | 2007-12-20 | Joey Moodley | Dihydropyrimidine Formulations |
| JP2009530385A (ja) | 2006-03-22 | 2009-08-27 | マウント シナイ スクール オブ メディシン | うつ病の治療のためのケタミンの鼻内投与 |
| FR2912591B1 (fr) * | 2007-02-12 | 2009-05-01 | Oberthur Card Syst Sa | Procede et dispositif pour controler l'execution d'au moins une fonction dans un module de communication sans fil de courte portee d'un appareil mobile. |
| AR062239A1 (es) * | 2007-08-07 | 2008-10-22 | Civil De Estudios Superiores A | Composicion farmaceutica sinergica util para inhibir la neovascularizacion (angiogenesis) corneal y retinal, y de otros organos, en un humano o animal |
| US20120070487A1 (en) * | 2010-03-24 | 2012-03-22 | Aegis Therapeutics Llc | Alkylsaccharide compositions with nutraceuticals |
| GB201401904D0 (en) * | 2014-02-04 | 2014-03-19 | Ziarco Pharma Ltd | Pharmaceutical composition for topical administration |
| CN108024997A (zh) * | 2015-07-17 | 2018-05-11 | 奥维德医疗公司 | 用加波沙朵治疗发育障碍的方法 |
| HRP20250215T1 (hr) * | 2016-04-12 | 2025-06-20 | Tonix Pharma Limited | Formulacije oksitocina koje sadrže magnezij i postupci upotrebe |
| WO2018013811A1 (en) * | 2016-07-14 | 2018-01-18 | The Regents Of The University Of California | Diagnostic and methods of treatment for chronic fatigue syndrome and autism spectrum disorders |
| WO2018148580A1 (en) * | 2017-02-09 | 2018-08-16 | Perfect Daylight Limited | Methods for autism spectrum disorder pharmacotherapy |
| US11110060B2 (en) * | 2017-10-25 | 2021-09-07 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for delivering pharmaceutical agents |
-
2020
- 2020-05-02 JP JP2021572548A patent/JP7749169B2/ja active Active
- 2020-05-02 WO PCT/US2020/031217 patent/WO2020247127A1/en not_active Ceased
- 2020-05-02 US US17/615,673 patent/US20220226268A1/en not_active Abandoned
- 2020-05-02 EP EP20818146.1A patent/EP3979985A4/en active Pending
- 2020-05-02 CN CN202080055332.3A patent/CN114340597B/zh active Active
- 2020-05-02 CA CA3142842A patent/CA3142842A1/en active Pending
- 2020-05-02 AU AU2020288999A patent/AU2020288999A1/en not_active Abandoned
-
2021
- 2021-12-02 IL IL288655A patent/IL288655A/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017529916A (ja) | 2014-09-02 | 2017-10-12 | トゥール・フランソワ=ラブレー大学 | 流体製品の鼻腔スプレー装置 |
| WO2018148262A1 (en) | 2017-02-08 | 2018-08-16 | Csp Pharma, Inc. | Antipurinergic compounds and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| GHADIRI, M. et al.,Strategies to Enhance Drug Absorption via Nasal and Pulmonary Routes,Pharmaceutics,2019年03月,11(3):113,<DOI: 10.3390/pharmaceutics11030113> |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220226268A1 (en) | 2022-07-21 |
| EP3979985A4 (en) | 2023-05-03 |
| CA3142842A1 (en) | 2020-12-10 |
| IL288655A (en) | 2022-02-01 |
| JP2022535920A (ja) | 2022-08-10 |
| WO2020247127A1 (en) | 2020-12-10 |
| EP3979985A1 (en) | 2022-04-13 |
| AU2020288999A1 (en) | 2022-02-03 |
| CN114340597B (zh) | 2025-01-28 |
| CN114340597A (zh) | 2022-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114340597B (zh) | 用于治疗中枢神经系统障碍的组合物和方法 | |
| US9585893B2 (en) | Flumazenil complexes, compositions comprising same and uses thereof | |
| ES2784843T3 (es) | Complejos de Sirolimus y sus derivados, procedimiento para la preparación de los mismos y composiciones farmacéuticas que los contienen | |
| JP2025087858A (ja) | トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療 | |
| US9572825B2 (en) | Compositions and methods for treating huntington's disease | |
| JP2015145430A (ja) | 薬剤の経口による生物学的利用能を向上させる方法及びより毒性の少ないオロチン酸塩組成物 | |
| US20160120865A1 (en) | Topical treatment of localized scleroderma | |
| US20230390223A1 (en) | Administration of antipurinergic compositions for treating nervous system disorders | |
| US20230390226A1 (en) | Intranasal administration of suramin for treating nervous system disorders | |
| CZ2003966A3 (cs) | Farmaceutický prostředek obsahující sloučeninu modafinilu v roztoku | |
| US20240277641A1 (en) | Methods for treating nervous system disorders with antipurinergic agents | |
| ES2729208T3 (es) | Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular | |
| HK40073161B (en) | Compositions and methods for treating central nervous system disorders | |
| HK40073161A (en) | Compositions and methods for treating central nervous system disorders | |
| JP2019536769A (ja) | 粘膜活性剤送達 | |
| EP4479048B1 (en) | Bilastine composition for once-daily parenteral administration | |
| IL227742A (en) | Plumzanil complexes, compounds containing them and their uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230427 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230515 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240419 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240524 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241021 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250131 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250428 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250618 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250730 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20250801 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20250815 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7749169 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |